Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Deckert

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Drug Targets|February 10, 2009
Current constructs and targets in clinical development for antibody-based cancer therapyP M Deckert
Cancer Chemotherapy and Pharmacology|April 29, 2004
Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancerG Hütter, H Szélenyi, P M Deckert, et al.
Mini Reviews in Medicinal Chemistry|June 22, 2010
Targeted enzyme prodrug therapiesN Schellmann, P M Deckert, D Bachran, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 15, 1996
CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccinationP M Deckert, M Ballmaier, S Lang, et al.
British Journal of Cancer|March 20, 2003
A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapyP M Deckert, C Renner, L S Cohen, et al.
International Journal of Cancer|July 18, 2000
Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenograftsP M Deckert, A Jungbluth, N Montalto, et al.
Scientific Reports|July 2, 2017
Diagnostic Performance of Contrast Enhanced Pulmonary Computed Tomography Angiography for the Detection of Angioinvasive Pulmonary Aspergillosis in Immunocompromised PatientsC Henzler, T Henzler, D Buchheidt, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Drug Targets|February 10, 2009
Current constructs and targets in clinical development for antibody-based cancer therapyP M Deckert
Cancer Chemotherapy and Pharmacology|April 29, 2004
Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancerG Hütter, H Szélenyi, P M Deckert, et al.
Mini Reviews in Medicinal Chemistry|June 22, 2010
Targeted enzyme prodrug therapiesN Schellmann, P M Deckert, D Bachran, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 15, 1996
CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccinationP M Deckert, M Ballmaier, S Lang, et al.
British Journal of Cancer|March 20, 2003
A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapyP M Deckert, C Renner, L S Cohen, et al.
International Journal of Cancer|July 18, 2000
Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenograftsP M Deckert, A Jungbluth, N Montalto, et al.
Scientific Reports|July 2, 2017
Diagnostic Performance of Contrast Enhanced Pulmonary Computed Tomography Angiography for the Detection of Angioinvasive Pulmonary Aspergillosis in Immunocompromised PatientsC Henzler, T Henzler, D Buchheidt, et al.
Pageof 1